Adherium announced that the Food and Drug Administration (FDA) has granted clearance for the over-the-counter (OTC) sale of its Smartinhaler sensor for Symbicort (budesonide, formoterol; AstraZeneca) inhaler.
The SmartTouch for Symbicort sensor is installed onto the patient’s inhaler to monitor usage and enhance medication adherence. Three buttons on the sensor help patients access audio visual reminders, battery status, and Bluetooth wireless technology. The sensor documents the exact date and time the inhaler was used and sends this data to the patient’s phone or tablet app. The recorded usage patterns can be reviewed by a physician to guide clinical decision-making.
Symbicort, a corticosteroid and long-acting beta-2 agonist (LABA) combination aerosol inhaler, is indicated to treat asthma in patients ≥6 years old not adequately controlled on a long-term asthma control medication (eg, inhaled corticosteroid [ICS]) or whose disease warrants initiation of both an ICS and LABA.
The SmartTouch device will be available OTC through pharmacies and online.
For more information call (650) 446-8589 or visit Adherium.com.